BioWorld Science: The Daily Drug R&D News Source

Enara validates first dark antigen cancer target, unveils bispecific T-cell engager
Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated regions of the dark genome, describing its findings in talks and posters being presented at the Society of Immunotherapy in Cancer (SITC) meeting in National Harbor, Md., Nov. 5-9, 2025.

Ulipristal reprograms breast tissue, cutting cancer-prone cells
Blocking progesterone receptor (PR) activity has long been viewed as a possible approach to breast cancer prevention. Historically, most supporting evidence came from animal models, epidemiological studies or mechanistic pathway analyses. Now, a team at the University of Manchester has uncovered direct mechanistic and clinical evidence that PR antagonists can reprogram the breast tissue microenvironment, suggesting a novel avenue for reducing breast cancer risk in women.

Enara validates first dark antigen cancer target, unveils bispecific T-cell engager
Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated regions of the dark genome, describing its findings in talks and posters being presented at the Society of Immunotherapy in Cancer (SITC) meeting in National Harbor, Md., Nov. 5-9, 2025.
Ulipristal reprograms breast tissue, cutting cancer-prone cells
Blocking progesterone receptor (PR) activity has long been viewed as a possible approach to breast cancer prevention. Historically, most supporting evidence came from animal models, epidemiological studies or mechanistic pathway analyses. Now, a team at the University of Manchester has uncovered direct mechanistic and clinical evidence that PR antagonists can reprogram the breast tissue microenvironment, suggesting a novel avenue for reducing breast cancer risk in women.
NME Digest: Q3 2025
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter.
Mwyngil Therapeutics in-licenses GPR75 modulators
Mwyngil Therapeutics Inc. has in-licensed several lead GPR75 modulator molecules and a proprietary cell-surface discovery platform from Expert Systems Inc.
Cue Biopharma and Immunoscape partner on cell therapy approach
Cue Biopharma Inc. and Immunoscape Pte. Ltd. have entered into a collaboration and license agreement for the treatment of solid tumors.
Bivision Pharmaceuticals patents new radiolabeled conjugates
Bivision Pharmaceuticals (Shanghai) Co. Ltd. has disclosed peptide-drug conjugates reported to be useful for diagnosis and treatment of fibrosarcoma.
MT-4561 exerts antitumor efficacy in NUT carcinoma
NUT carcinoma is a rare and aggressive cancer tied to the BRD4-NUT fusion protein, with poor prognosis and lack of effective therapy.
AAX Biotech and Toxotech collaborate in neurological disorders
AAX Biotech AB and Toxotech AB have established a strategic collaboration to advance next-generation biotherapeutics.

Today's news in brief

BioWorld

BioWorld MedTech

BioWorld Asia

BioWorld Science

BioWorld Premium